The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ:IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ.The decision was based on a review of the results of a single-arm clinical trial in 100 adults with BCG-unresponsive NMIBC who received Anktiva in combination with BCG.In 71% of patients, signs of cancer disap ...